Viona Pharmaceuticals Inc. has secured an approval for its DMF waiver on the generic label for metformin hydrochloride, opening the door to significant market traction as producers navigate complex regulatory hurdles. This development is expected to enhance the company’s revenue streams by removing a critical constraint on bulk manufacturing and strengthening its dominance within the oral antidiabetic landscape.